Cumbre Pharmaceuticals And Global Alliance For TB Drug Development Announce Partnership To Develop New Agents For Tuberculosis Therapy

DALLAS & NEW YORK--(BUSINESS WIRE)--Cumbre Pharmaceuticals Inc, a Dallas-based biopharmaceutical company, and the Global Alliance for TB Drug Development (TB Alliance), a public-private partnership developing affordable new TB drugs, today announced plans to pursue a joint program to develop new, promising anti-tuberculosis agents.

Back to news